Contracts › 75N91022C00015
75N91022C00015: Sbir Phase Ii - Topic 396 - Imaging for Cancer Immunotherapies
Awarded to Cellsight Technologies, Inc. by National Institutes of Health (NIH).
$2.0Mobligated
$2.0Mpotential value
15 September 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N91022C00015 |
|---|---|
| Awardee | Cellsight Technologies, Inc. |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NIH NCI |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | CA |
| Offers received | 2 |
| Period of performance | 16 September 2022 to 15 September 2026 |
| Potential end | 15 September 2026 |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record